MKC-963 is an orally active and potent inhibitor targeting platelet aggregation-related pathways. MKC-963 exerts antithrombotic activity by inhibiting platelet aggregation, and can also induce autoinduction, i.e., upregulating the mRNA expression and activity of CYP3A4 enzyme to accelerate its own metabolism in vivo. MKC-963 is promising for research of platelet aggregation-related diseases (e.g., thrombosis).
Products | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Cardiovascular Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > Platelet-activating Factor Receptor (PAFR)
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.